Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial

计划入组 140 人 · 首次发布于 2015 年 10 月 16 日

Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial

计划入组 140 人 · 首次发布于 2011 年 6 月 21 日

Formycon's FYB206, a Keytruda Biosimilar, Enters Clinical Development Amidst Strong Financial Results

Formycon Expands Global Reach for Eylea Biosimilar Through Strategic Partnerships with Teva and Lotus Pharmaceutical